Why SIGA Technologies (SIGA) Is One of the Most Profitable Pharmaceutical Stocks Right Now?

Insider Monkey12-01

We recently published a list of 12 Most Profitable Pharmaceutical Stocks Right Now. In this article, we are going to take a look at where SIGA Technologies, Inc. (NASDAQ:SIGA) stands against the other...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488685348?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gpPc8DzBF1lBLUCzPLuqRw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/480949fdcb5391bbd3e0d76f6c3f12ca","is_english":true,"pubTime":"2024-12-01 05:22","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2488685348","market":"us","top_or_hot":-1,"title":"Why SIGA Technologies (SIGA) Is One of the Most Profitable Pharmaceutical Stocks Right Now?","media":"Insider Monkey","content":"<div>\n<p>We recently published a list of 12 Most Profitable Pharmaceutical Stocks Right Now. In this article, we are going to take a look at where SIGA Technologies, Inc. (NASDAQ:SIGA) stands against the other...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-siga-technologies-siga-one-212245135.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why SIGA Technologies (SIGA) Is One of the Most Profitable Pharmaceutical Stocks Right Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy SIGA Technologies (SIGA) Is One of the Most Profitable Pharmaceutical Stocks Right Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-01 05:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/why-siga-technologies-siga-one-212245135.html><strong>Insider Monkey</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We recently published a list of 12 Most Profitable Pharmaceutical Stocks Right Now. In this article, we are going to take a look at where SIGA Technologies, Inc. (NASDAQ:SIGA) stands against the other...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-siga-technologies-siga-one-212245135.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SQQQ","symbol_name":"纳指三倍做空ETF","start_time":0,"source_url":"https://finance.yahoo.com/news/why-siga-technologies-siga-one-212245135.html","article_id":"2488685348","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gpPc8DzBF1lBLUCzPLuqRw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/480949fdcb5391bbd3e0d76f6c3f12ca"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488685348","pubTimestamp":1733001765,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We recently published a list of 12 Most Profitable Pharmaceutical Stocks Right Now. In this article, we are going to take a look at where SIGA Technologies, Inc.  stands against the other most profitable pharmaceutical stocks.The Pharmaceutical Industry: Growth, Innovation, and Emerging Challenges. Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools and tests, takes the term \"defensive\" a step further than practically any other industry. Improvements in medical technology, medications, and therapeutic approaches have changed the course of patient care. As the need for quick results has grown, pharmaceutical corporations in particular have drawn much attention. Global pharmaceutical manufacturing was estimated to be worth $516.48 billion in 2022, according to a Grand View Research analysis. From 2023 to 2030, the industry is expected to expand at a compound annu","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SQQQ":"纳指三倍做空ETF",".IXIC":"NASDAQ Composite","CAGR":"California Grapes International, Inc.","QID":"纳指两倍做空ETF","SIGA":"SIGA Technologies Inc","BK4583":"猴痘概念","PSQ":"纳指反向ETF","BK4159":"经销商","BK4007":"制药","QLD":"纳指两倍做多ETF","TQQQ":"纳指三倍做多ETF"},"translate_title":"为什么SIGA Technologies(SIGA)是目前最赚钱的制药股之一？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAGR":1,"SIGA":1,".IXIC":0.9,"MNQmain":0.6,"NQmain":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"We recently published a list of 12 Most Profitable Pharmaceutical Stocks Right Now. In this article, we are going to take a look at where SIGA Technologies, Inc. (NASDAQ:SIGA) stands against the other most profitable pharmaceutical stocks.\nThe Pharmaceutical Industry: Growth, Innovation, and Emerging Challenges\nHealthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools and tests, takes the term \"defensive\" a step further than practically any other industry. Improvements in medical technology, medications, and therapeutic approaches have changed the course of patient care. As the need for quick results has grown, pharmaceutical corporations in particular have drawn much attention. Global pharmaceutical manufacturing was estimated to be worth $516.48 billion in 2022, according to a Grand View Research analysis. From 2023 to 2030, the industry is expected to expand at a compound annual growth rate (CAGR) of 7.63%.\nThe biopharma industry now has the most extensive and varied clinical pipeline, due to decades of groundbreaking research. In 2012, there were 3,200 distinct medications under development; by 2022, that number had nearly doubled to 6,100. The average cost of producing a single treatment is over $1 billion, while just 14% of medications in clinical trials reach FDA clearance, according to MIT research. This could be a game-changer for AI. To identify the optimum medicine combinations, generative AI, for instance, helps researchers identify illness patterns in large data sets and explore a far greater number of possible compounds than traditional approaches can. Additionally, according to PwC, AI-driven analytics and automation could cut operational costs by more than 30% and process timeframes by 60–70%.\nIn a similar vein, the market has grown significantly due to consumer interest in weight-loss medications like Ozempic and Wegovy. According to a recent study in the scientific journal Addiction, GLP-1 medications may reduce the prevalence of alcohol and opioid addiction by as much as 50%. Additionally, these medications are being evaluated for Alzheimer's disease and other disorders that are frequently associated with obesity. The development of GLP-1 is becoming crucial for pharmaceutical businesses that want to be leaders in fields like cardiovascular and renal health. Competition with the leading companies in the anti-obesity business, which is expected to grow to $130 billion by 2030, is no longer the main emphasis. The possibility of additional participants entering the field is growing along with the possible applications of GLP-1s.\nThe pharmaceutical industry faces challenges despite appearing robust. Biotech and pharma funding dropped 48.6% in 2022 compared to 2021, with IPO proceeds also declining amid market volatility. While 2020 and 2021 saw drug-developer IPOs raise $46.5 billion, surpassing the previous eight years combined, investor caution has increased. In 2024, drug developers raised $2 billion through IPOs by September 3, a 24% year-over-year increase. However, two-thirds of these funds came early in the year, with proceeds falling sharply later, reducing their share of U.S. IPO proceeds from 17% in February to 6.5%.\nIn his October 7 remarks, Tim Hunt, CEO of the Alliance for Regenerative Medicine, highlighted increased 2024 investment in cell and gene therapies, noting that 13 of the 15 largest pharma companies are active in this space. With numerous patents expiring, these therapies offer potential revenue opportunities. However, Q2 2024 saw a 38% drop in cell and gene therapy deals compared to 2023, alongside fewer patent applications. Despite these challenges, the field remains a strong investment prospect.\n A researcher holding a pipette in a laboratory, symbolizing the company's sustained innovation. \nOur Methodology \nOur methodology focuses on identifying high-growth stocks by applying a rigorous Stock Analysis filter. We considered companies with positive net income growth for 5 years and then ranked them accordingly. We also measured hedge fund sentiment around each stock according to Insider Monkey’s database of 900 as of Q3 2024.\nWhy are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).\nSIGA Technologies, Inc. (NASDAQ:SIGA)\nNet Income Growth 5Y:\nSIGA Technologies, Inc. (NASDAQ:SIGA) is a commercial-stage pharmaceutical company that specializes in the health security market, particularly in the United States. It is one of the best profitable stocks in the pharmaceutical industry.\nIn the third quarter of 2024, SIGA Technologies, Inc. (NASDAQ:SIGA) reported strong financial performance which was driven by robust procurement orders and diverse revenue sources. The company secured $122 million in procurement orders, surpassing the previous year’s performance. Key revenue drivers included $53 million in product sales, with $23 million from oral TPOXX and $17 million from IV TPOXX sales to the US Government, as well as $12 million from international sales. SIGA Technologies, Inc. (NASDAQ:SIGA) also earned $4 million in research and development revenues.\nThe growth is primarily attributed to increased demand for TPOXX, its antiviral drug for smallpox and orthopoxviruses, with a $112.5 million order from the US Government under the 19C contract. The corporation achieved a pre-tax operating income of $13 million which is a notable improvement from a loss last year, and net income of $13 million for the nine months ending September 30, 2024, with a fully diluted income per share of $0.19.\nLooking ahead, SIGA Technologies, Inc. (NASDAQ:SIGA) is preparing for a new long-term agreement with the US Government in 2025 and is expanding internationally, with a recent sale of TPOXX to Morocco marking its entry into Africa. Additionally, the company is developing monoclonal antibodies in collaboration with Vanderbilt University which is supported by funding from the US Department of Defense, which could open new growth opportunities.\nOverall, SIGA ranks 9th on our list of most profitable pharmaceutical stocks right now. While we acknowledge the potential of pharmaceutical companies, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SIGA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.\nREAD NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.\nDisclosure: None. This article is originally published at Insider Monkey.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488685348"}